BioStock: Medivir announce improved durable clinical benefit with fostrox

Medivir, whose ongoing rights issue ends today December 21, has announced that the lasting clinical benefit from the ongoing phase Ib/IIa study in advanced hepatocellular carcinoma continues to improve. According to the company, these data provide further support for accelerating the development program with fostrox and initiating a pivotal phase IIb study in second-line HCC in 2024.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/medivir-announce-improved-durable-clinical-benefit-with-fostrox/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/